The PREVENT program is a peer-reviewed agent development program designed to support preclinical development of innovative interventions and biomarkers for cancer prevention and interception towards clinical trials. All interested researchers with novel concepts are eligible to apply. PREVENT is not a grant program, but allocates NCI contract resources and expertise to generate data and materials, which are used by the applicants for further development. PREVENT’s current research priority areas include immunoprevention, chemoprevention, and clinically translatable biomarkers.
Read more About PREVENT.
Submission deadlines occur twice per year on the second Monday in January and July.
Next deadline: Monday, July 10, 2023
Instructions for Applying
Please use the latest
120 Projects from PREVENT Cycles 1 through 21:
- 72 Chemoprevention projects
- 39 Immunoprevention projects
- 9 Biomarker projects
Read more about supported projects and supported prevention approaches.
- Efficacy and Intermediate Endpoint Biomarker Work
- Toxicology and Pharmacology Testing
- CGMP Production of Vaccines and Biologicals
- Prime Contractors 2019–2023
- Animal Models Used by PREVENT
- Governance Structure
- Technology Transfer Considerations
News and Events
2023 “Investigators' and Site Coordinators' Opportunity for Research Excellence” (I-SCORE) HYBRID meeting
Date Posted: February 8, 2023
Translational Advances in Cancer Prevention Agent Development (TACPAD) – 2nd Biennial Virtual Meeting
Date Posted: May 31, 2022
DCP/PREVENT-funded Project Presentations at the 2022 AACR Annual Meeting
Date Posted: April 1, 2022
DCP/PREVENT-funded Project Presentations at AACR Virtual Annual Meeting I, April 9-15 2021
Date Posted: April 23, 2021